Estrogen receptor agonists

Psidial A
Catalog No: CFN99321

Psidial A shows activity to enzyme PTP1B; it also reduces tumor growth and stimulate uterus proliferation.
Calycosin
Catalog No: CFN99140

Calycosin, a selective estrogen receptor modulator, is also a vasorelaxant and a noncompetitive Ca(2+) channel blocker. It has anti-oxidative, anti-inflammatory, hepatoprotective,antineoplastic, and effective skin-lightening activities. Calycosin exhibited tyrosinase inhibitory activity with an IC(50) value of 38.4 microM, it suppressed breast cancer cell growth via ERβ-dependent regulation of IGF-1R, p38 MAPK and PI3K/Akt pathways.
Liquiritigenin
Catalog No: CFN99156

Liquiritigenin, is an estrogenic compound which acts as an agonist selective for the β-subtype of the estrogen receptor, possesses anti-inflammatory, antihyperlipidemic, and antiallergic effects. Liquiritigenin can dose dependently alleviate mechanical, thermal and cold hyperalgesia, it may be potentially useful novel treatments for neuropathic pain. It exhibits antitumour action in pituitary adenoma cells via Ras/ERKs and ROS-dependent mitochondrial signalling pathways.
trans-Hinokiresinol
Catalog No: CFN99834

Hinokiresinol is a novel inhibitor of LTB4 binding to the human neutrophils, it has antiallergic effect, it inhibits IgE-induced mouse passive cutaneous anaphylaxis reaction. Hinokiresinol (trans-hinokiresinol) and nyasol (cis-hinokiresinol) are estrogen agonists, they possess appreciable estrogen receptor binding activity, they can stimulate the proliferation of estrogen- dependent T47D breast cancer cells, and their stimulatory effects could be blocked by an estrogen antagonist. They have similar free radical scavenging and anti-inflammatory activities, they also have anti-ischemic effects, only trans-hinokiresinol can significantly decrease neuronal injury in cultured cortical neurons exposed to oxygen-glucose deprivation followed by re-oxygenation.
Medicarpin
Catalog No: CFN98411

Medicarpin, a legume phytoalexin, acts as an estrogen receptor (ER) agonist, can stimulate osteoblast differentiation likely via ERβ, promote achievement of peak bone mass, and is devoid of uterine estrogenicity; in addition, given its excellent oral bioavailability, it can be potential osteogenic agent. Medicarpin sensitizes myeloid leukemia cells to TRAIL-induced apoptosis through the induction of DR5 and activation of the ROS-JNK-CHOP pathway. Medicarpin also has antifungal activity.